These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25976222)

  • 1. Modeling the heterogeneous intestinal absorption of propiverine extended-release.
    Weiss M; Sermsappasuk P; Siegmund W
    Eur J Pharm Sci; 2015 Aug; 76():133-7. PubMed ID: 25976222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of a fat-rich meal on bioavailability of extended-release and immediate-release propiverine.
    Siegmund W; Siegert J; Richter K; Schnabel F; Feustel C; Kirch W
    J Clin Pharmacol; 2012 May; 52(5):681-90. PubMed ID: 21551317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition and antimuscarinic effects of the urinary bladder spasmolytics propiverine: influence of dosage forms and circadian-time rhythms.
    May K; Westphal K; Giessmann T; Wegner D; Adam U; Lerch MM; Oertel R; Warzok RW; Weitschies W; Braeter M; Siegmund W
    J Clin Pharmacol; 2008 May; 48(5):570-9. PubMed ID: 18319360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination.
    May K; Giessmann T; Wegner D; Oertel R; Modess C; Oswald S; Braeter M; Siegmund W
    Eur J Clin Pharmacol; 2008 Nov; 64(11):1085-92. PubMed ID: 18626633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic basis for unexpected bioavailability enhancement of polyelectrolyte complexes incorporating BCS class III drugs and carrageenans.
    Heinen C; Reuss S; Saaler-Reinhardt S; Langguth P
    Eur J Pharm Biopharm; 2013 Sep; 85(1):26-33. PubMed ID: 23958316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects.
    Abebe BT; Weiss M; Modess C; Tadken T; Wegner D; Meyer MJ; Schwantes U; Neumeister C; Scheuch E; Schulz HU; Tzvetkov M; Siegmund W
    J Clin Pharmacol; 2020 Mar; 60(3):312-323. PubMed ID: 31542894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dependence of Bioavailability on Mean Absorption Time: What Does It Tell Us?
    Weiss M; Siegmund W
    AAPS J; 2023 Apr; 25(3):36. PubMed ID: 37016156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the P-Glycoprotein Inhibitor Clarithromycin on the Pharmacokinetics of Intravenous and Oral Trospium Chloride: A 4-Way Crossover Drug-Drug Interaction Study in Healthy Subjects.
    Abebe BT; Weiss M; Modess C; Roustom T; Tadken T; Wegner D; Schwantes U; Neumeister C; Schulz HU; Scheuch E; Siegmund W
    J Clin Pharmacol; 2019 Oct; 59(10):1319-1330. PubMed ID: 30973998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing the solubility and masking the bitter taste of propiverine using crystalline complex formation.
    Ogata T; Tanaka D; Ozeki T
    Drug Dev Ind Pharm; 2014 Aug; 40(8):1084-91. PubMed ID: 23789589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible.
    Reddy MB; Connor A; Brennan BJ; Morcos PN; Zhou A; McLawhon P; Fretland A; Evans P; Smith P; Tran JQ
    Biopharm Drug Dispos; 2011 Jul; 32(5):261-75. PubMed ID: 21660978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of trospium-specific absorption models for fasted and fed states in humans.
    Cvijić S; Langguth P
    Biopharm Drug Dispos; 2014 Dec; 35(9):553-8. PubMed ID: 25044357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
    Appell RA; Chancellor MB; Zobrist RH; Thomas H; Sanders SW
    Mayo Clin Proc; 2003 Jun; 78(6):696-702. PubMed ID: 12934778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of an oral prolonged-release antibiotic formulation.
    Schneider H; Nightingale CH; Quintiliani R; Flanagan DR
    J Pharm Sci; 1978 Nov; 67(11):1620-2. PubMed ID: 712604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimuscarinic drug inhibits detrusor overactivity induced by topical application of prostaglandin E2 to the urethra with a decrease in urethral pressure.
    Yokoyama O; Miwa Y; Oyama N; Aoki Y; Ito H; Akino H
    J Urol; 2007 Nov; 178(5):2208-12. PubMed ID: 17870108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination effect of physical and gustatory taste masking for propiverine hydrochloride orally disintegrating tablets on palatability.
    Matsui R; Uchida S; Namiki N
    Biol Pharm Bull; 2015; 38(1):17-22. PubMed ID: 25744453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: muscarinic receptor binding and pharmacokinetics.
    Yamada S; Ito Y; Taki Y; Seki M; Nanri M; Yamashita F; Morishita K; Komoto I; Yoshida K
    Drug Metab Dispos; 2010 Aug; 38(8):1314-21. PubMed ID: 20483954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained delivery of intact drug to the colon: mesalamine formulation and temporal gastrointestinal transit analysis.
    Chuong MC; Christensen JM; Ayres JW
    Pharm Dev Technol; 2009; 14(1):116-25. PubMed ID: 18821272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo evaluation under finite conditions of a transdermal oil-in-water type emulsified formulation of propiverine hydrochloride.
    Matsui R; Uchida S; Namiki N
    Biol Pharm Bull; 2014; 37(10):1661-7. PubMed ID: 25273389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
    Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.